Galmed Pharmaceuticals Ltd
GPH
Company Profile
Business description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Contact
16 Tiomkin Street
Tel Aviv6578317
ISRT: +972 36938448
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
stocks
Ask the analyst: Is the market underestimating Bapcor?
This moated ASX company's shares are in a prolonged slump. I quizzed our analyst Angus Hewitt on its management, the potential impact of EVs, and more.
stocks
Is our ASX best idea still attractive after shares surge?
Shares rose over 21% following the results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,752.50 | 4.90 | 0.06% |
CAC 40 | 8,006.22 | 33.19 | 0.42% |
DAX 40 | 21,911.74 | 124.74 | 0.57% |
Dow JONES (US) | 44,470.41 | 167.01 | 0.38% |
FTSE 100 | 8,767.80 | 67.27 | 0.77% |
HKSE | 21,395.73 | 126.25 | -0.59% |
NASDAQ | 19,714.27 | 190.87 | 0.98% |
Nikkei 225 | 38,801.17 | 14.15 | 0.04% |
NZX 50 Index | 12,917.45 | 41.10 | 0.32% |
S&P 500 | 6,066.44 | 40.45 | 0.67% |
S&P/ASX 200 | 8,485.00 | 2.20 | 0.03% |
SSE Composite Index | 3,316.83 | 5.34 | -0.16% |